Laraway Financial Advisors Inc Sells 250 Shares of CVS Health Co. (NYSE:CVS)

Laraway Financial Advisors Inc lessened its stake in shares of CVS Health Co. (NYSE:CVS) by 7.5% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 3,085 shares of the pharmacy operator’s stock after selling 250 shares during the quarter. Laraway Financial Advisors Inc’s holdings in CVS Health were worth $138,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Coppell Advisory Solutions LLC increased its stake in CVS Health by 17.3% during the 4th quarter. Coppell Advisory Solutions LLC now owns 1,282 shares of the pharmacy operator’s stock valued at $56,000 after purchasing an additional 189 shares in the last quarter. EagleClaw Capital Managment LLC increased its stake in CVS Health by 3.4% during the 4th quarter. EagleClaw Capital Managment LLC now owns 6,135 shares of the pharmacy operator’s stock valued at $275,000 after purchasing an additional 200 shares in the last quarter. Manchester Capital Management LLC increased its stake in CVS Health by 4.8% during the 4th quarter. Manchester Capital Management LLC now owns 4,457 shares of the pharmacy operator’s stock valued at $200,000 after purchasing an additional 204 shares in the last quarter. Angeles Investment Advisors LLC increased its stake in CVS Health by 3.7% during the 4th quarter. Angeles Investment Advisors LLC now owns 5,706 shares of the pharmacy operator’s stock valued at $256,000 after purchasing an additional 204 shares in the last quarter. Finally, Rogco LP increased its stake in CVS Health by 3.2% during the 4th quarter. Rogco LP now owns 6,752 shares of the pharmacy operator’s stock valued at $303,000 after purchasing an additional 210 shares in the last quarter. Institutional investors own 80.66% of the company’s stock.

CVS Health Price Performance

Shares of NYSE CVS opened at $66.98 on Monday. The business has a 50-day moving average of $66.96 and a 200-day moving average of $59.06. The company has a market capitalization of $84.73 billion, a price-to-earnings ratio of 18.30, a PEG ratio of 0.98 and a beta of 0.60. CVS Health Co. has a 1-year low of $43.56 and a 1-year high of $72.51. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.81 and a quick ratio of 0.60.

CVS Health (NYSE:CVS) last released its quarterly earnings results on Thursday, May 1st. The pharmacy operator reported $2.25 earnings per share for the quarter, beating analysts’ consensus estimates of $1.62 by $0.63. The business had revenue of $94.59 billion during the quarter, compared to analyst estimates of $93.07 billion. CVS Health had a net margin of 1.24% and a return on equity of 9.11%. The business’s revenue was up 7.0% on a year-over-year basis. During the same period last year, the business earned $1.31 EPS. On average, equities analysts anticipate that CVS Health Co. will post 5.89 EPS for the current fiscal year.

CVS Health Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, May 1st. Investors of record on Tuesday, April 22nd were given a $0.665 dividend. The ex-dividend date of this dividend was Tuesday, April 22nd. This represents a $2.66 annualized dividend and a yield of 3.97%. CVS Health’s dividend payout ratio is presently 63.48%.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on CVS shares. Evercore ISI increased their price objective on shares of CVS Health from $60.00 to $65.00 and gave the stock an “outperform” rating in a research note on Monday, January 27th. Leerink Partnrs upgraded shares of CVS Health from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 12th. Argus set a $77.00 price target on shares of CVS Health in a research report on Tuesday, February 18th. Mizuho raised their price target on shares of CVS Health from $70.00 to $76.00 and gave the company an “outperform” rating in a research report on Wednesday, April 9th. Finally, Wells Fargo & Company restated an “overweight” rating and set a $84.00 price target (up previously from $76.00) on shares of CVS Health in a research report on Tuesday, May 6th. Three equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, CVS Health currently has a consensus rating of “Moderate Buy” and an average target price of $74.81.

Insider Activity at CVS Health

In other news, SVP James David Clark sold 7,513 shares of CVS Health stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $66.35, for a total value of $498,487.55. Following the transaction, the senior vice president now owns 8,394 shares of the company’s stock, valued at $556,941.90. The trade was a 47.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Michael F. Mahoney acquired 30,000 shares of the stock in a transaction dated Tuesday, February 18th. The stock was acquired at an average cost of $66.70 per share, for a total transaction of $2,001,000.00. Following the purchase, the director now directly owns 39,356 shares in the company, valued at approximately $2,625,045.20. The trade was a 320.65% increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.22% of the stock is currently owned by insiders.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.